What You Need to Know
Hospitals across the Hackensack Meridian Health network are now offering Pluvicto, a new, life-changing targeted treatment option for patients with prostate-specific membrane antigen-positive (PSMA+) metastatic prostate cancer who have exhausted all other lines of treatment.
Pluvicto is clinically proven to extend survival for patients with PSMA+ metastatic prostate cancer who have experienced disease progression despite treatment with androgen receptor pathway inhibitors and chemotherapy. Pluvicto is the first and only FDA-approved PSMA-targeted radioligand therapy (RLT).
How Pluvicto Works
Pluvicto is a targeted therapy that works by binding to and destroying PSMA+ cancer cells throughout the body — including bone, nodal and visceral metastases — and is associated with fewer side effects when compared to chemotherapy treatment. The drug is delivered via injection every six weeks for up to six treatments during a 10-minute outpatient radiology procedure.
Benefits for Your Patients
Referring your patients to Hackensack Meridian Health for treatment with Pluvicto may provide benefits, including:
- Close-to-home access to the latest targeted treatment option for metastatic prostate cancer
- An additional treatment option after all other lines of therapy have been exhausted
- Improved survival
- Enhanced quality of life
- Convenient treatment administration
- Fewer side effects when compared to chemotherapy